Cyclica is developing advanced molecules that embrace the complexity of the disease. Traditional drug discovery often ends in failure and only targets a small subset of proteins. Cyclica is instead exploring the unexplored using new-age AI to unlock the protein universe and discover the medicines of tomorrow. To achieve this, Cyclica has built a generalizable platform using their two machine-learning engines (MatchMakerTM and POEMTM) that can match the chemical universe to the entire protein universe. The platform features protein structure-prediction technology such as AlphaFold2 so Cyclica can focus on both low and high data protein targets. With a focus currently on oncology and CNS diseases, Cyclica hopes to accelerate drug discovery from molecule to medicine.

Cyclica

Founded: 2010
Location: Toronto, ON
Employee range: 50 - 200
Funding: C$23M B Jun 2020

Short description:

Drug notes:

Long description:

Jobs: